Artivion, INC Form 4 insider transactions

ARTIVION's Chief Commercial Officer, John E. Davis, reported the sale of 5,000 shares of common stock at $45.11 per share on December 15, 2025, executed under a pre-arranged Rule 10b5-1 plan.

ARTIVION's VP, Chief Accounting Officer, Amy Horton, sold 4,572 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Artivion, Inc. President and CEO James P. Mackin exercised stock options and subsequently sold 30,921 shares of common stock under a pre-arranged 10b5-1 trading plan.

Artivion's SVP, General Counsel, Jean F. Holloway, sold 7,315 shares of common stock for approximately $331,489.50 on December 3, 2025, under a pre-arranged 10b5-1 trading plan.

Artivion, Inc. President & CEO James P. Mackin exercised stock options and subsequently sold 30,921 shares of common stock under a pre-arranged 10b5-1 trading plan.

Artivion's VP, Chief Accounting Officer, Amy Horton, reported gifting 750 shares of common stock to a charity.

Artivion's SVP of Clinical & MD Affairs, Marshall S. Stanton, exercised stock options and subsequently sold an equivalent number of common shares in pre-planned transactions.

Artivion's SVP of Clinical & MD Affair, Marshall S. Stanton, sold common stock on November 20, 2025, following the exercise of stock options.

Artivion Director Elizabeth A. Hoff reported the sale of 4,200 shares of common stock at a weighted average price of $45.098, executed under a Rule 10b5-1 plan.

Artivion's SVP and General Counsel, Jean F. Holloway, executed pre-planned sales of common stock following the exercise of stock options.

Artivion's Chief Commercial Officer, John E. Davis, exercised stock options and subsequently sold shares of common stock in planned transactions.

ARTIVION's VP, Chief Accounting Officer, Amy Horton, sold 6,000 shares of common stock for approximately $45.73 per share.

ARTIVION's VP, Chief Accounting Officer, Amy Horton, sold 3,482 shares of common stock at $45.858 per share to cover tax withholding obligations related to restricted stock unit vesting.

Artivion's Chief Commercial Officer, John E. Davis, sold 6,563 shares of common stock at $45.858 per share to cover tax withholding obligations related to restricted stock unit vesting.

Artivion, Inc. President and CEO James P. Mackin sold 34,210 shares of common stock at $45.858 per share to cover tax withholding obligations related to RSU vesting.

ARTIVION's SVP, General Counsel, Jean F. Holloway, sold 5,761 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Artivion's SVP of Clinical & MD Affair, Marshall S. Stanton, sold 4,993 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

ARTIVION's SVP, General Counsel, Jean F. Holloway, reported insider transactions involving stock option exercise and share sales under a 10b5-1 plan.

ARTIVION, Inc. President & CEO James P. Mackin sold 17,580 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

ARTIVION's Chief Commercial Officer, John E. Davis, sold 3,373 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

ARTIVION's VP, Chief Accounting Officer, Amy Horton, reported a future sale of 1,789 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Artivion's SVP of Clinical & MD Affair, Marshall S. Stanton, sold 2,566 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Artivion's SVP of Clinical & MD Affairs, Marshall S. Stanton, exercised stock options and subsequently sold 18,200 shares of common stock for a significant profit.

Artivion's SVP, General Counsel, Jean F Holloway, exercised stock options and subsequently sold 10,000 shares of common stock for a significant gain.

ARTIVION, Inc. President and CEO James P. Mackin sold 12,500 shares of common stock for approximately $529,000 on August 15, 2025, under a pre-arranged trading plan.

Artivion's SVP and General Counsel, Jean F. Holloway, exercised stock options and subsequently sold a portion of her common stock holdings.

Artivion's Chief Commercial Officer, John E. Davis, has disclosed a pre-planned exercise of stock options and subsequent sale of common stock scheduled for August 12, 2025.

ARTIVION's VP, Chief Accounting Officer, Amy Horton, exercised stock options and immediately sold the acquired shares under a pre-arranged 10b5-1 trading plan.

Artivion, Inc. SVP Marshall S. Stanton sold 15,000 shares of common stock for $29.50 per share under a Rule 10b5-1 trading plan.

Marshall S. Stanton, SVP of Clinical & MD Affairs at Artivion, Inc., has sold a total of 26,132 shares of common stock on June 13, 2025, through a pre-arranged 10b5-1 trading plan.